2017 Executive Sponsors

Foundation Medicine
Mitra Biotech

2017 Associate Sponsors

Adaptive Biotechnologies
Affimed
Inovio
Personalis
SignalRX Pharmaceuticals
Vyriad

2017 Educational Partners

CRI
SITC

2017 Media Partners

Biocompare
BioPharm Insight
BioPharma Dive
CanBiotech
Clinical Leader
Life Science Leader
MNT
Pharmaceutical Online
Pharmalicensing
pharmaphorum
PharmaVOICE
SciDoc Publishers
Technology Networks

2017 Featured Speakers


Industry and Academic Leaders Address Scientific, Clinical and Business Developments in IO Combination Strategies to Fight a Wider Range of Cancers

” The aim is to create transformational medicines, with bigger effects for mono-therapies or combinations” ~ Dr Axel Hoos, SVP, Oncology R&D, GSK


Overview

Lead advisors Dr Patrick Hwu, MD Anderson, Dr Ian McCaffery, Corvus Pharmaceuticals and Dr Axel Hoos, GSK, presented the 2nd annual Rational Combinations 360° program that addressed business aspects, clinical advancements and scientific data in IO combination strategies to fight a wider range of cancers.

Understanding and determining how to apply certain IO combinations for the right patients and specific tumor types is arguably the most difficult challenge within cancer immunotherapy.

Rational Combinations 360° provided the most up-to-date research, data and progress on combination developments to help IO stakeholders:

  • Be at the forefront of the most relevant research and developments for IO combinations from key leadership who are at the pulse of cancer immunotherapy
  • Better understand what assets are available for potential combinations that may be able to give patients more treatment options
  • Create and prioritize combination strategies targeted toward specific tumor types
  • Foster collaboration amongst others working in all aspects of cancer immunotherapy by rounding up all stakeholders under one roof

The Rational Combinations 360° event concentrated on the following key areas:

  • Derisking of Combination Immunotherapies
  • Clinical Combination Immunotherapies
  • Immuno Resistance – Drivers for Combination Therapy
  • Novel Technologies and Emerging Biomarkers
  • Clinical Manifestations of Immunological Toxicities
  • Business Aspects for Combination Immunotherapy

Sincerely,

Kate-BW-2

 

 

Kate Woda
Conference Director

Valerie Bowling New

 

 

Valerie Bowling
Executive Director

 

 

Meredith Sands
Executive Director, Business Development

Elizabeth Bard B&W-47

 

 

Elizabeth Bard
Business Development Manager

geeta-new-bw

 

 

Geeta Bachani
Business Development Manager

Nancy-BW-2

 

 

Nancy Belis
Conference Planner & Logistics

 

 

Onalee Smith
Marketing Manager


Testimonials

  • "I absolutely enjoyed the meeting! It was great getting both academia and industry together to discuss how we move forward."

    - Robert Andtbacka, Huntsman Cancer Institute

  • "Thanks so much for putting on a great conference. It was very informative and I was excited to be a part of it. I am looking forward to the next one!"

    - Amanda Bruno, GSK

  • "It was a great conference. I learned a lot and enjoyed the diversity of speakers"

    - Julia Keith, RA Capital

  • "It was great meeting. I really enjoyed the conference and my interactions with several of the participants."

    - Jeffrey Wallin, Genentech